Penumbra (PEN) FCF Margin Growth (1y) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | -80.00 |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | 473.00 |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | 23.00 |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | -431.00 |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | -1,716.00 |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | 2,811.00 |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | 2,833.00 |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | 192.00 |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | 261.00 |
| 10 | Penumbra | 12.52 Bn | 11.91 Bn | 253.41 Mn | 861.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 861.00 |
| Dec 31, 2025 | 86.00 |
| Sep 30, 2025 | 723.00 |
| Jun 30, 2025 | 261.00 |
| Mar 31, 2025 | -70.00 |
| Dec 31, 2024 | 422.00 |
| Sep 30, 2024 | 929.00 |
| Jun 30, 2024 | -143.00 |
| Mar 31, 2024 | 783.00 |
| Dec 31, 2023 | 1,739.00 |
| Sep 30, 2023 | 1,667.00 |
| Jun 30, 2023 | 2,859.00 |
| Mar 31, 2023 | 847.00 |
| Dec 31, 2022 | 1,155.00 |
| Sep 30, 2022 | -2,682.00 |
| Jun 30, 2022 | -1,930.00 |
| Mar 31, 2022 | 514.00 |
| Dec 31, 2021 | -1,137.00 |
| Sep 30, 2021 | 1,000.00 |
| Jun 30, 2021 | 2,520.00 |
| Mar 31, 2021 | 191.00 |
| Dec 31, 2020 | -448.00 |
| Sep 30, 2020 | -683.00 |
| Jun 30, 2020 | -2,812.00 |
| Mar 31, 2020 | -941.00 |
| Dec 31, 2019 | -322.00 |
| Sep 30, 2019 | 552.00 |
| Jun 30, 2019 | 162.00 |
| Mar 31, 2019 | -1,229.00 |
| Dec 31, 2018 | 1,342.00 |
| Sep 30, 2018 | -198.00 |
| Jun 30, 2018 | 136.00 |
| Mar 31, 2018 | 1,138.00 |
| Dec 31, 2017 | -45.00 |
| Sep 30, 2017 | 760.00 |
| Jun 30, 2017 | 1,146.00 |
| Mar 31, 2017 | 414.00 |
| Dec 31, 2016 | 2,035.00 |
| Sep 30, 2016 | 897.00 |
| Jun 30, 2016 | -42.00 |
| Mar 31, 2016 | 309.00 |
| Dec 31, 2015 | -83.00 |